

Rapha Capital PE Life Sciences Fund VI

Identifying potentially disruptive life sciences and healthcare companies within a sea of less compelling opportunities.

The Rapha Capital Mission is to use our unique abilities to identify those companies that we believe will go on to profoundly improve peoples' lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities.

In [Rapha Capital PE Life Sciences Fund VI, LP](#), our new [Private Equity](#) fund, we plan to maintain our focus on identifying great value in these times of market disruption in the life sciences and healthcare arena to add investments in mid- and later- stage companies in which we can be transformative.

Disclaimer

THIS IS NOT AN OFFERING OR THE SOLICITATION OF AN OFFER TO PURCHASE AN INTEREST. ANY SUCH OFFER OR SOLICITATION WILL BE MADE TO QUALIFIED INVESTORS ONLY BY MEANS OF A FINAL OFFERING MEMORANDUM AND ONLY IN THOSE JURISDICTIONS IN WHICH PERMITTED BY LAW.


AN INVESTMENT IN THE FUND IS SPECULATIVE AND INVOLVES A HIGH DEGREE OF RISK. OPPORTUNITIES FOR WITHDRAWAL/REDEMPTION AND TRANSFERABILITY OF INTERESTS ARE RESTRICTED, SO INVESTORS MAY NOT HAVE ACCESS TO CAPITAL WHEN IT IS NEEDED. THERE IS NO SECONDARY MARKET FOR THE INTERESTS AND NONE IS EXPECTED TO DEVELOP. THE PORTFOLIO, WHICH IS UNDER THE SOLE TRADING AUTHORITY OF THE GENERAL PARTNER/INVESTMENT MANAGER, IS PRIMARILY CONCENTRATED IN AN EARLY-STAGE BIOTECH INVESTMENT STRATEGY AND THIS LACK OF DIVERSIFICATION MAY RESULT IN HIGHER RISK.

AN INVESTOR SHOULD NOT MAKE AN INVESTMENT, UNLESS IT IS PREPARED TO LOSE ALL OR A SUBSTANTIAL PORTION OF ITS INVESTMENT. THE FEES AND EXPENSES CHARGED IN CONNECTION WITH THIS INVESTMENT MAY BE HIGHER THAN THE FEES AND EXPENSES OF OTHER INVESTMENT ALTERNATIVES AND MAY OFFSET PROFITS.


THERE IS NO GUARANTEE THAT THE INVESTMENT OBJECTIVE WILL BE ACHIEVED. MOREOVER, THE PAST PERFORMANCE (IF ANY) OF THE INVESTMENT TEAM SHOULD NOT BE CONSTRUED AS AN INDICATOR OF FUTURE PERFORMANCE.

Fund Overview

- Experienced Investment Team
 - A decade of experience guiding early-stage biotech company to IPO
 - Founder of Bellicum Pharmaceuticals, Inc. in 2004
 - \$500M IPO in 2014
 - Identified Immunotherapy as a disruptive technology in oncology in 2004 before others realized the impact
 - Identified Robotic Surgery as a disruptive technology in medicine in 2001 before others realized the impact
- Successful Track Record in Early-Stage Biotech Investing
 - ~3-year exit horizon on investment targets in our VC fund
- Historic reset in life science valuations have created unique opportunities in a wider range of healthcare-focused companies, including those that are mid- and later- stage
 - ~5-year exit horizon
 - Addition of healthcare focused-companies with cash flow to our portfolio



Management Team

- Kevin Slawin, MD – Founder and Managing Partner
 - Founder of Bellicum Pharmaceuticals (NASDAQ: BLCM)
 - Board member at 3DBio Therapeutics, Inc. (<https://3dbiocorp.com/>), FIZE Medical, Inc. (www.fizemedical.com), and Demeetra AgBio, Inc. (www.demeetra.com)
 - Served as a board member and interim CEO of portfolio company AsclepiX Therapeutics, Inc. (www.asclepix.com) in 2020, engineering their \$35 million Series A financing led by Perceptive Xontogeny Venture Fund in mid 2020
 - Founder of Ponce Therapeutics, Inc. (<https://poncetherapeutics.com>) and DELiver Therapeutics, Inc. (<https://delivertherapeutics.com>)
 - Board Chairman of Imagin Medical, Inc. (<https://imaginmedical.com>), a public company on the CST and OTC
- Kayvon Namvar – Investment Diligence, Market Research and Financial Modeling
 - RNA Advisors - Principal
- Rob Del Prete – Fund Administrator
 - RDP Fund Services, LLC – Managing Partner
 - Previously Manager, Fund Administration at 

Our Edge

Rapha Capital Management's Founder, Dr. Kevin Slawin, has a unique mix of experience as a robotic oncologic surgeon, academician, basic and clinical researcher, inventor, entrepreneur, biotech founder and investor, as well as public biotech operator. This enables him to sift through the myriad of early-stage biotech investment opportunities to "bend the curve" towards a higher success rate than is typically seen in this category and stage of investments.

Furthermore, Dr. Slawin's previous experience founding, growing and operating the Vanguard Urologic Institute in the Texas Medical Center, and his deep experience as a clinician treating patients with the most difficult problems in urologic oncology has given him the skills needed to evaluate investment opportunities in the healthcare space with a broad insight into their potential commercial success.

Adding to this expertise, RNA Advisors has worked with a large number of biotech, medtech, healthcare IT, and healthcare services firms over the years. They have worked with operators and investors of healthcare services firms e.g., dialysis centers, hospitals, assisted living facilities, SNFs, oncology practices, dentist offices, and others, in addition to the product developers that sell products used by such services firms.

Investment Philosophy and Strategy

Rapha Capital Management, the Investment Manager is focused on identifying and growing revolutionary and disruptive ideas in medicine, healthcare, and biotechnology, before others can see their value. The Partnership executes its investment strategy by making equity and debt investments in both privately held companies at early, mid- and late-stage, and in some cases, public companies, that RCM believes have developed a transformative product, technology, or process that will drive medium- and long-term value creation for shareholders. The Partnership will invest primarily in U.S. companies

Terms

| | |
|-------------------------------------------|--------------------------------------------------------------------|
| Minimum Investment | \$250,000 |
| Term | Fund launch Sept. 30, 2022, closes to new investors Sept. 30, 2023 |
| | 7-year term with two 1-year optional extensions |
| Fund Manager | Kevin Slawin MD/Rapha Capital and the Investment Committee |
| Capital Calls | 100% of capital due upon closing |
| Management Fee | 2% per year |
| Preferred Return | 8% |
| Incentive Fee | 20% after return of capital and preferred return |
| Administrator/Fund Accountant | RDP Fund Services |
| Legal Counsel | Investment Law Group |
| Investment Diligence / Financial Analysis | RNA Advisors |
| Other Advisors | TBD on a deal-by-deal basis |
| Target Fund Size | \$50M to \$100M |

Directory

| | |
|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| The Partnership: | Rapha Capital PE Life Sciences Fund VI, LP c/o Rapha Capital PE Life Sciences Fund GP, LLC 9511 Collins Ave., #1403 Surfside, Florida 33154 Tel: (305) 809-6920 |
| The Investment Manager: | Rapha Capital Management, LLC 9511 Collins Ave., #1403 Surfside, Florida 33154 Tel: (305) 809-6920 Email: info@raphap.com |
| Counsel to General Partner: | The Investment Law Group of Davis Gillett Mottern & Sims LLC 545 Dutch Valley Road, NE, Suite A Atlanta, Georgia 30324 Tel: (404) 607-6940 |
| Administrator: | RDP Fund Services LLC 23 Evelyn Ct. Brick, New Jersey 08723 Tel: (732) 773-3149 Email: rob.delprete@rdpfundservices.com |